Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03338166

Enrollment

Registered

2017-11-09

Start date

2018-01-02

Completion date

2018-12-31

Last updated

2017-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Brief summary

Hepatocellular carcinoma represents the commonest primary cancer of the liver.serum lactate dehydrogenase is an indirect marker of tumor hypoxia,angioneogenesis and worse prognosis.

Detailed description

Hepatocellular carcinoma (HCC) represents the commonest primary cancer of the liver. Incidence is increasing and HCC has risen to become the 5th commonest malignancy worldwide and the third leading cause of cancer related death, exceeded only by cancers of the lung and stomach. HCC prevalence is higher in sub-Saharan Africa, central and Southeast Asia.Serum lactate dehydrogenase (LDH) levels is an indirect marker of tumor hypoxia, angioneogenesis and worse prognosis. Lactic dehydrogenase (LDH), which is a glycolytic enzyme, composed of four polypeptide chains, each one encoded by separate gene (M and H), exists in various types of human tissue and neoplasms. LDH is a key enzyme in the conversion pyruvate to lactate under anaerobic conditions .Five isoforms of LDH have been identified as a result of the five different combinations of polypeptide subunits. Hypoxia represents a clinical biological mechanism for treatment resistance in cancer cells via the formation of new blood vessels. Furthermore, a growing body of evidence indicates that hypoxia might actually promote cancer development.

Interventions

OTHERLDH serum level

Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* patients with Hepatocellular carcinoma diagnosed by biopsy or imaging criteria and alpha feto protein. * signed informed consent before registration in study * Eastern Cooperative oncology Groups Performance status between 0 and 2.

Exclusion criteria

* Cachexia or poor condition * pregnant or human chorionic gonadotropin positive * patient with another liver tumor * Any previous treatment

Design outcomes

Primary

Measure	Time frame	Description
serum LDH level as a predictor of response in hepatocellular carcinoma	2 months	To evaluate if serum LDH level can be used as a predictor of response in patients receiving different lines of treatment for hepatocellular carcinoma

Contacts

Primary ContactSamir S Mohammed, Professor

samir_eid@hotmail.com00201222302375

Backup ContactMarwa I Khalaf, Lecturer

esmail_marwa@yahoo.com00201201777338

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026